Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Abbott Completes Separation of Research-Based Pharmaceuticals Business



    Abbott Completes Separation of Research-Based Pharmaceuticals Business

  PR Newswire

  ABBOTT PARK, Illinois, Jan. 2, 2013

- Major Milestone Marks 125th Anniversary of Company's Founding

- Continues Diverse Healthcare Leadership in Diagnostics, Medical Devices,
Nutrition and Branded Generic Pharmaceuticals

- Set to Deliver Industry-Leading Growth, Expanding Margins and Strong Cash
Flow

- Businesses Aligned With Long-Term Healthcare and Patient Trends,
Particularly in Fastest-Growing Economies

ABBOTT PARK, Illinois, Jan. 2, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) today
announced it has completed the separation of its research-based
pharmaceuticals business, which became AbbVie, a new independent
biopharmaceutical company. AbbVie will begin trading independently on the New
York Stock Exchange today under the symbol "ABBV."

On Nov. 28, 2012, Abbott's board of directors declared a special dividend
distribution of all outstanding shares of AbbVie common stock. For every 1
share of Abbott common shares held as of close of business on Dec. 12, 2012,
Abbott shareholders received 1 share of AbbVie common stock on Jan. 1, 2013.

Abbott announced in October 2011 that it was separating into two independent
companies, as its businesses evolved into two different investment identities.
AbbVie is a research-based specialty biopharmaceuticals company with a broad
portfolio of medicines, including leadership in immunology and virology, and a
pipeline of breakthrough therapies. Abbott is one of the largest
science-based, diversified healthcare companies, with market-leading offerings
in diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals.

"We wish our colleagues at AbbVie continued success as they become part of a
new, independent company that is already making a significant difference,
focusing on highly specialized, market-leading therapies for some of the
world's most difficult-to-treat diseases," said Miles D. White, chairman and
chief executive officer, Abbott.

"Abbott has taken the most transformative action in its 125-year history,"
said Mr. White. "We have had enduring success precisely because of what we're
doing now – reinventing ourselves for changing times and creating new ways to
serve the millions of patients, customers, communities and shareholders who
depend on us."

Strength Through Diversity Abbott begins its 125th year with approximately $22
billion in revenues generated throughout 150 countries and remains one of the
largest and most far-reaching global healthcare companies, with diversity
across technologies, businesses and geographies.

The company is comprised of four businesses of roughly equal size –
diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals. Abbott's businesses are all leaders in their respective
fields and hold the top market positions across numerous categories. These
businesses develop leading, science-based products that are meeting the needs
of patients and consumers in the evolving global healthcare environment.

Abbott is well positioned to deliver reliable performance with
industry-leading growth, expanding margins and strong cash flow. The company's
businesses are aligned with long-term health trends, including the world's
aging population, increasing prevalence of chronic disease, and improving
access to care in fast-growing economies. Continued investment in new
technologies is advancing Abbott's offerings in vascular health, diabetes
care, diagnostic screening and detection, vision correction and nutrition
science.

Revenue among Abbott's businesses is well balanced geographically, with 30
percent generated in the United States, 30 percent from Western Europe,
Canada, Japan and Australia, and 40 percent from the fastest-growing
economies, including India, China, Russia and Brazil. The company's presence
in these high-growth markets is among the most expansive of any diversified
healthcare company and is expected to reach nearly 50 percent of sales by
2015.

About Abbott Abbott is a global healthcare company devoted to improving life
through the development of products and technologies that span the breadth of
healthcare. With a portfolio of leading, science-based offerings in
diagnostics, medical devices, nutritionals and branded generic
pharmaceuticals, Abbott serves people in more than 150 countries and employs
approximately 70,000 people.

Visit Abbott at www.abbott.com and connect with us on Twitter at @AbbottNews.

– Private Securities Litigation Reform Act of 1995 – A Caution Concerning
Forward-Looking Statements Some statements in this news release may be
forward-looking statements for purposes of the Private Securities Litigation
Reform Act of 1995, including Abbott's expected financial results after the
separation. Abbott cautions that these forward-looking statements are subject
to risks and uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Economic, competitive,
governmental, technological and other factors that may affect Abbott's
operations are discussed in Item 1A, "Risk Factors," to our Annual Report on
Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2011
and in Item 1A, "Risk Factors," to our quarterly report on Securities and
Exchange Commission Form 10-Q for the quarter ended September 30, 2012 and
June 30, 2012, and are incorporated by reference. Abbott undertakes no
obligation to release publicly any revisions to forward-looking statements as
a result of subsequent events or developments, except as required by law.

Website: http://www.abbott.com
Contact: Media, Scott Stoffel, +1-847-936-9502 or Scott Davies,
+1-847-938-8898, or Financial, Brian Yoor, +1-847-937-6343 or Tina Ventura,
+1-847-935-9390
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement